Johnson & Johnson Q4 Profit Decreases

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you're an income investor, your primary focus is ...
Stifel analyst Rick Wise lowered the firm’s price target on Johnson & Johnson to $155 from $170 and keeps a Hold rating on the shares.
The 47-year-old millionaire tech mogul posted screenshots showing data from an overnight erection-tracking machine for both himself and his 19-year-old son, Talmage.